Improving stroke treatment with robotics

Image source: Robocath

News • Co-development research program

Improving stroke treatment with robotics

Medical robotics company Robocath and Rennes University Hospital announce the launch of a co-development research program using robotics to improve treatment for stroke victims.

With the support of Philips France, this program will be implemented over the next four years. It will focus on the use of robotics in treating strokes, the second most common cause of death globally after myocardial infarctions. The program will begin with a clinical study into the treatment of carotid artery disease using R-One, the first robotic platform developed by Robocath, which has been on the market since 2019. This first-generation robotic solution was designed to improve the treatment of cardiovascular disease by enhancing physicians’ movements through increased precision. It also helps medical staff to drastically reduce their exposure to X-rays.

Precision of movement is a key factor in treating stroke patients; the use of robotics will increase the success rate of these procedures

François Eugène

Following the clinical study, the partnership will become an active R&D collaboration aimed at improving and enhancing current and future generations of robotic solutions, based on the synergy between both parties’ skills and know-how. 

Dr. François Eugène, Interventional Neuroradiologist at Rennes University Hospital, said: “I am delighted to be launching this scientific research partnership with Robocath and to be working with this passionate team. Robotics is already successfully used to treat coronary disease in humans. The benefits of this technology can also be applied to the treatment of certain neurovascular diseases. This is largely because precision of movement is a key factor in treating stroke patients; the use of robotics will increase the success rate of these procedures. I’m very excited to get started on the clinical study.”

Philippe Bencteux, President and Founder of Robocath, explained: “This unique partnership will enable Robocath to enter the next phase of its development strategy. The research program opens up promising new avenues for both our current and future generations of robotic solutions.”

Lucien Goffart, Robocath’s CEO, added: “This collaboration proves that there is considerable interest in robotics in the medical sector. It demonstrates the whole scope of potential applications in a range of specialist vascular fields. The combination of Dr. Eugène’s enthusiasm and the support of Philips France is the ideal recipe for the success of this research program, which will undoubtedly represent a pivotal moment in our company’s history.”


Source: Robocath

07.07.2021

Read all latest stories

Related articles

Photo

News • Chronotype, duration, apnea and more

How sleep impacts cardiovascular health

A new study shows five aspects of sleep that are almost equally important to explain the association between sleep and the risk of coronary events and stroke.

Photo

News • Overlooked by most doctors

Income and ethnicity identified as risk factors for cardiovascular disease

According to Dutch researchers, people with low income are up to 1.5 times more at risk of a heart attack or stroke than their wealthier compatriots. Ethnicity was also identified as a risk factor.

Photo

Video • Telerobotic intervention

Joystick-operated robot could help remote surgical stroke treatment

Engineers at the Massachusetts Institute of Technology (MIT) have developed a telerobotic system to help surgeons quickly and remotely treat patients experiencing a stroke or aneurysm.

Related products

Subscribe to Newsletter